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Abstract 
The encapsulation of glucocorticoids such as dexamethasone in nanoparticles faces two main issues: 
a low drug loading and the destabilization of the nanoparticle suspension due to drug crystallization. 
Here, we successfully formulated a prodrug of dexamethasone, dexamethasone palmitate (DXP), into 
nanoparticles stabilized by the sole presence of DSPE-PEG2000. Two formulation processes, 
nanoprecipitation, and emulsion-evaporation allowed the formation of stable nanoparticles. By 
adjusting the drug/lipid ratio and the DXP concentration nanoparticles of DXP (DXP-NPs) with a size 
comprised between 130 and 300nm can be obtained. Owing to the presence of DSPE-PEG2000, a high 
drug entrapment efficiency of 98%w/w was reached for both processes, corresponding to a very high 
equivalent dexamethasone drug loading around 50%w/w with the absence of crystallization upon 
storage at 4°C. The anti-inflammatory activity of DXP-NPs was preserved when incubated with 
macrophages activated with lipopolysaccharide. Pharmacokinetics parameters were evaluated after 
intravenous (IV) injection of DXP-NPs to healthy mice. The release of DXM from DXP-NPs in plasma 
was clearly controlled up to 18 hours compared to the free drug which was rapidly eliminated from 
plasma after administration. In conclusion, a novel type of nanoparticle combining the advantages of 
prodrugs and nanoparticles was designed, easy to produce with a high loading efficiency and leading 
to modified pharmacokinetics and tissue distribution after IV administration. 
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1 INTRODUCTION  
Glucocorticoids (GCs) have a long history as anti-inflammatory and immunosuppressive drugs but 
their use is limited due to their side effects which become critical during long term therapy.1,2 To 
improve GCs pharmacokinetics and increase their concentrations in inflamed therapeutic sites, the 
use of PEGylated nanocarriers has been considered because of their prolonged circulation in the 
blood stream3 and their passive diffusion through highly permeable vasculature of inflamed tissues. 4 
However, in the case of GCs and many other drugs, nanocarriers suffer from several drawbacks such 
as the low drug loading, the difficulty to entrap hydrophobic drugs5,6 and the premature burst 
release5,7,8 that severely hinders their clinical translation. Indeed, most physically entrapped active 
molecules present a drug loading comprised between 0.1 and 10%.9 This low proportion of active 
drug per nanocarrier directly leads to the administration of high quantities of potentially harmful 
excipients such as surfactants, stabilizers (poloxamers, poly(vinyl alcohol), tween 80…), lipids or 
polymers. Stability of the nanosuspension may also be an issue for hydrophobic drugs. Indeed, over 
time, the entrapped drug is susceptible to be released in the media and crystallization is often 
observed due to Ostwald ripening.5,6,10,11 In addition, the physical entrapment is often associated 
with a premature drug release once the formulation is injected intravenously12. Tsotas et al. 
demonstrated the influence of lipid composition of liposomes on dexamethasone (DXM) entrapment 
efficiency but never reached above 0.5 DXM/lipid molar ratio.13 Entrapment of dexamethasone or 
dexamethasone acetate into poly(lactide-co-glycolide) nanoparticles led to a low drug loading of 0.2 
and 0.6% w/w respectively.5,6 In addition, drug crystallization was observed inducing the 
destabilization of the nanosuspension and the burst release was very important.5,6 More recent 
approaches to overcome the low loading efficiency issue consisted in encapsulating within colloidal 
nanocarriers lipophilic prodrugs from GCs such as palmitate derivatives.14–18 For instance, 
prednisolone palmitate or dexamethasone palmitate have been incorporated into liposomes with a 
high entrapment efficiency.16,19 The presence of strong hydrophobic interactions between the alkyl 
chain of the prodrug and those of lipids forming liposomes membrane can explain the stable 
retention of the prodrug in the nanocarrier.20 A lipid nanoemulsion containing dexamethasone 
palmitate (DXP), Limethason® or Lipotalon®, is currently on the market in Japan and Germany, 
indicated for rheumatoid arthritis and osteoarthritis via intra-articular injection.21,22 Although being a 
crucial parameter, the burst release issue was not approached here. Therefore, to improve drug 
loading and limit burst release, nanocarriers consisting in solely prodrugs have been proposed.23–26 
In the present report, a novel approach was used to formulate DXP directly into nanoparticles using a 
biocompatible and biodegradable lipid, Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-2000)] (DSPE-PEG2000) as crystallization inhibitor and colloidal stabilizer. 
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Nanoprecipitation and emulsion-evaporation processes were tested and compared in terms of 
nanoparticle size, polydispersity index, surface charge, stability, DSPE-PEG2000, and DXP entrapment 
efficiency and internal morphology. The optimal formulation obtained thanks to the emulsion-
evaporation process with DXP/DSPE-PEG2000 concentrations of 5/2.5mg/mL was characterized for in 
vitro cytotoxicity and anti-inflammatory efficiency on activated macrophages. In vivo studies on mice 
were conducted to determine the pharmacokinetics and biodistribution showing enhanced 
pharmacokinetics and modified tissue distribution of the nanoparticle due to the dysopsonization 
effect of PEG. 
2 MATERIALS AND METHODS 
2.1 Materials 
Dexamethasone palmitate (DXP) was purchased from Interchim (France). DSPE-PEG2000 (1,2-
Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-(methoxy(polyethylene glycol)-2000) (ammonium 
salt)) was obtained from Avanti  Polar Lipids, Inc. (USA). Dexamethasone base (DXM) and 
dexamethasone acetate (DXA) were provided from Chemos GmbH (Germany). Testosterone 
decanoate (TesD) was obtained from Interchim (France). Dexamethasone disodium phosphate (DSP) 
was purchased from Fagron (The Netherlands). MilliQ water was purified using a RIOS system from 
Merck-Millipore (France). Chloroform HPLC-grade was obtained from Carlo Erba Reagents (France), 
methanol and acetonitrile HPLC-grade were purchased from VWR Chemicals (France). All 
experiments were performed in amber vials due to the photosensitivity of dexamethasone palmitate 
and DSPE-PEG2000  
2.2 Nanoparticle preparation 
Nanoparticles were formulated either by an emulsion-evaporation or a nanoprecipitation process to 
obtain seven targeted final concentrations of dexamethasone palmitate with the following 
DXP/DSPE-PEG2000 ratios: 1.25/0.625; 2.5/1.25; 5/2.5; 5/5; 5/7.5; 7.5/2.5; 10/5 in mg/mL 
For emulsion-evaporation, 10mL of milliQ water was prechilled at 4°C. The desired amounts of DXP 
(12.5; 25; 50; 75 or 100mg) and DSPE-PEG2000 (6.25; 12.5; 25; 50 or 75mg) were dissolved in 1mL 
chloroform. The organic phase was then injected into the water phase thanks to a solvent-
compatible syringe (Injekt®, B.Braun) and a 20Gx23/4 needle. The mixture was then pre-emulsified by 
vortexing for 30 seconds before being placed under ultrasonication during 2min at an amplitude of 
40% in an ice bath. The organic phase evaporation was performed under reduced pressure using a 
rotary evaporator (Büchi). After full evaporation of the solvent, the suspension volume was 
completed to 10 mL with Milli-Q water in a volumetric flask and nanoparticles were stored at 4°C 
protected from light.  
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For nanoprecipitation, DSPE-PEG2000 (6.25; 12.5; 25; 50 or 75mg) was dissolved in 5mL milliQ water at 
60°C. DXP (12.5; 25; 50; 75 or 100mg) was dissolved in 1mL acetone and then slowly injected into the 
aqueous phase under magnetic stirring. After 5min stirring, the preparation was evaporated under 
reduced pressure using a rotary evaporator. After full evaporation of the solvent, the suspension 
volume was completed to 10mL with Milli-Q water in a volumetric flask and nanoparticles were 
stored at 4°C protected from light. Osmolality was measured on a freezing point depression 
automatic micro osmometer (Type 13/13DR autocal, Roebling, Germany). 
2.3 Size and zeta potential measurement  
Size and zeta potential were determined with a Zetasizer Nano-ZS from Malvern Instrument (UK), 
based on quasi-elastic light scattering. The measurement was performed in triplicate at an angle of 
173° at 25°C. Hydrodynamic diameter (dH), polydispersity index (PdI) and zeta potential were 
recorded on 1/10 diluted samples in milliQ water for size measurements or in NaCl 1mM for zeta 
potential measurements. 
2.4 Transmission electron microscopy (TEM)  
Transmission electron microscopy was performed at I2BC (CNRS, Gif-sur-Yvette, France). A volume of 
5L of the nanoparticle suspension at 5mg/mL DXP was deposited for 1 minute on 400 mesh 
formwar-coated copper grids. Negative staining was performed by addition of a drop of uranyl 
acetate at 2% w/w for 30 seconds. Excess solution was removed and grids were left to dry before 
observation. The observations were carried out on a JEOL JEM-1400 microscope at an acceleration 
voltage of 80KV. Images were acquired using an Orius camera (Gatan Inc, USA). 
2.5 X-ray powder diffraction 
X-ray powder diffraction (XRPD) measurements were performed using a Rigaku rotating copper 
anode automated diffractometer operating at 50kV and 200mA using Cu Kα radiation. Nanoparticles 
suspensions were concentrated with Amicon 100kDa, the concentrate was gently introduced into 
quartz capillaries before sealing them. The intensity of the diffracted X-ray beam was measured as a 
function of the theta angle (1 to 60°). 
2.6 Entrapment efficiency 
After DXP nanoparticles (DXP-NPs) preparation, quantification of encapsulated DXP and DSPE-PEG2000 
was performed with HPLC coupled to an evaporative light-scattering detector (ELSD, Eurosep, Cergy, 
France) and a UV detector (785A, Applied Biosystems). DXP was detected with both detectors and 
DSPE-PEG2000 was only detected with ELSD detector. UV detection was performed at 240nm 
wavelength and ELSD detection settings were a nebulization temperature of 35°C and an evaporation 
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temperature of 45°C. An autosampler (Series 200, Perkin Elmer) was employed connected to a Perkin 
Elmer pump and both detectors UV and ELSD. The SymmetryShieldTM RP18 column (5 µm, 250×4.6 
mm; Waters, France) was maintained at room temperature, the mobile phase was composed of 
MeOH:ACN:Ammonium acetate (pH 4.00, 200mM) 70:20:10 added with 0.043% acetic acid and 
0.104% trimethylamine, flow rate was set at 1mL/min.  
To separate DXP-NPs form non-encapsulated molecules, ultracentrifugation was performed at 
40000rpm (=109760g) during 4h at 4°C (Beckman Coulter Optima LE-80K ultracentrifuge, 70-1Ti 
rotor). The supernatant was delicately removed to avoid resuspension of the pellet and freeze-dried 
for 24h (Alpha 1-2 LD Plus, Bioblock, France) after freezing in liquid nitrogen (-196°C). Lyophilisates 
were dissolved in methanol to reach suitable concentrations within the range of the calibration 
curve. A volume of 30µL of samples dissolved in MeOH was injected and analyzed during 12min. 
Retention times were 7min and 9min for DXP and DSPE-PEG2000, respectively. The concentration 
ranges of the calibration curves were 12.5-750µg/mL for DXP and 37.5-375µg/mL for DSPE-PEG2000. 
ELSD detection calibration curves followed a power law model, equations and correlation coefficients 
were y=219.71x1.2458, R²=0.9959 for DXP and y=144.12x1.2714, R²=0.9991 for DSPE-PEG2000, 
respectively. UV calibration curve of DXP followed a linear model, y=486.2x+4.6095, R²=0.9987. 
Entrapment efficiency was calculated as the DXP or DSPE-PEG2000 amount encapsulated compared to 
the initial amount weighted for the DXP-NPs preparation. Drug loading results correspond to the 
proportion equivalent DXM amount encapsulated compared to the total mass of the DXP-NPs. 
2.7 Surface PEG density 
PEG density at the surface of DXP-NPs 5mg/mL prepared through nanoprecipitation or emulsion-
evaporation was quantified using data presented thereafter. DXP-NPs density was calculated as an 
average between ratios of DXP=1.12g/cm
3 and DSPE-PEG2000=1g/cm
3 according to the entrapment 
efficiency of each component, the average diameter of the nanoparticles, the molar mass of DSPE-
PEG2000 is MDSPE-PEG=2805.54g/mol. Masses of DXP and DSPE-PEG2000 in NPs were respectively 50mg 
and 25mg with the respective percentages of encapsulated DXP and DSPE-PEG2000 depending on the 
technique used. 
Using these data, the surface area (Ssp, specific surface) of the suspension depends on    
(nanoparticle density) and dH (nanoparticle average diameter) and can be calculated as (Equation 1). 
Equation 1  Ssp = 
 
   
  
Thus, the available surface (Savailable) in a suspension can be calculated using Equation 2. 
Equation 2 Savailable=                      where mDXP and mDSPE-PEG are the actual masses of 
DXP and DSPE-PEG2000 found in a formulation. 
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The number of DSPE-PEG2000 in the suspension can be calculated using Equation 3  
Equation 3 NDSPE-PEG = 
         
         
      where NA is the Avogadro number 
Using these three values, it is possible to deduce the surface available per PEG chain on the surface 
of the nanoparticles (Equation 4). 
Equation 4 SurfacePEG = 
          
         
  
The PEG density is expressed as surface area (nm2) per PEG chain. 
2.8 Cell culture 
The murine macrophage cell line RAW 264.7 obtained from ATCC (USA) was cultured in 75 cm2 flask 
with 15 mL of DMEM supplemented with 10% FBS, 10 000 unit/mL of penicillin and 10 mg/mL of 
streptomycin, in a humidified incubator at 37°C supplied with 5% CO2. Cells were split twice per week 
at 1/10 ratio using a scraper to detach them and were used between passages 3 to 20 after thawing. 
2.9 Cell viability  
The influence of the DXP-NPs on cell viability was assessed using the MTT (3-[4,5-dimethylthiazol-2-
yl]-3,5-diphenyl tetrazolium bromide) colorimetric assay 27 that evaluates mitochondrial activity. Cells 
were seeded in 96-well plates (TTP, Zurich, Switzerland) at a density of 8x103 cells/well in 100 µL of 
culture medium, and were left overnight in the incubator. DXP-NPs were diluted in culture medium 
at various concentrations (37.5-450µg/mL DXP), 100µL of theses dilution were added on cells, the 
culture medium was used as a negative control. DXP-NPs alone in the culture medium, without cells, 
were also tested to check their potential interference with the MTT assay. Plates were incubated for 
24 hours and the yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide) was added at a final concentration of 500 µg/mL and incubated for another hour. The MTT 
is reduced by metabolically active cells to form the purple formazan crystals. After the formation of 
the crystals, the medium was discarded and replaced by 200 µL of dimethyl sulfoxide (DMSO) to 
dissolve crystals and the absorbance was measured at 570nm. The formula used to calculate cell 
viability was the following: (Abs: absorbance) 
                 
                             
                 
  100 
Following the same protocol, dexamethasone sodium phosphate (DSP) was tested as a positive 
control. Serial dilutions in culture medium were performed ranging from 41 to 657µg/mL DSP. To 
compare DXP-NPs and DSP, tested concentrations were calculated as dexamethasone base 
equivalents (eq.DXM), corresponding to the active drug. All measurements were performed in 
triplicate. 
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2.10 Cytokine quantification 
For the cytokine quantification, RAW 264.7 cells were seeded in 24-well plates at a cell density of 
4x104 cells/well in culture medium and were incubated for 48 hours until 80% confluency. Then, the 
medium was replaced by fresh medium alone or fresh medium with LPS at 0.1 µg/mL to induce 
inflammation, and plates were incubated another 3 hours. Afterwards, nanoparticles produced by 
emulsion-evaporation (5/2.5 mg/mL DXP/DSPE-PEG2000) at three concentrations diluted in culture 
medium: 1, 10 and 100µg/mL of DXP and free dexamethasone phosphate (DSP) at 82µg/mL in 
culture medium, which correspond to 100µg/mL DXP considering molecular weight ratio, were 
added. Culture medium alone was used as negative control and LPS 0.1 µg/mL as a positive control. 
After 24 hours of incubation with the treatments, cell supernatants were collected and frozen at 
-20°C until analysis was performed. Cells were detached and counted. Mouse inflammatory cytokines 
TNFα, MCP-1, IL-10, and IL-6 were quantified using a Cytometric Beads Array (CBA) detection kit (BD 
Biosciences, USA). In each test tube, 50µL of mouse inflammation capture bead suspension was 
added, completed with either 50µL of standards solution (20-5000pg/mL) or 50µL of supernatants 
samples. Phycoerythrin (PE) detection reagent was added 50µl to each tube and incubation during 2h 
at room temperature was performed. Samples were washed with 1mL wash buffer provided in the 
kit and tubes were centrifuged (200g, 5min) to recover the pellet. 300µL of wash buffer was added to 
resuspend the pellet and samples were quantified with the BD Accuri C6 Cytometer (BD Biosciences, 
USA). Cytokines results were analyzed with the FACP Array™ Software and were obtained as pg/mL 
concentrations. All measurements were performed in triplicate. Statistical analysis was performed 
with two-way ANOVA followed by Tukey’s post-test using GraphPad Prism. 
2.11 In vivo studies 
In vivo experimental procedures using DBA/1OlaHsd mice were approved by the ethical committee 
No 026 and by the French ministry of education and research (Accepted protocol No 2842-
2015110914248481_v5). The number of animals was determined according to the power analysis 
method 28. 9-12-week-old male DBA/1OlaHsd mice were purchased from Envigo (UK) and let for one 
week after shipping for adaptation before starting experiments. Mice were kept in a separate animal 
room under climate-controlled conditions with a 12h light/dark cycle, housed in polystyrene cages 
containing wood shavings and fed standard rodent chow and water ad libitum. Mouse colonies were 
screened and determined to be pathogen-free. 
2.12 Pharmacokinetics and biodistribution 
Nanoparticles prepared by emulsion-evaporation 5/2.5 mg/mL (DXP/DSPE-PEG2000) as described 
above were half-diluted in PBS to obtain a final concentration of 2.5mg/mL DXP, which corresponds 
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to an equivalent of 1.55mg/mL DXM. A control of dexamethasone disodium phosphate (DSP) in PBS 
was prepared to obtain a final concentration of 1.55mg/mL (eq. DXM). DBA/1OlaHsd male mice aged 
10-12 weeks were divided into two groups. One group was administered with the nanoparticle 
suspension and the other received the control. The administration was performed by IV injection in 
the tail vein at 12mg/kg (eq. DXM), an intermediate dose in the range found in the literature for 
efficacy in mice (1-60mg/kg)25,29. For each group, 10 pharmacokinetics time points were selected 
with 7 mice per time point. Blood sampling was achieved by terminal cardiac puncture using a 25G 
needle while mice were previously deeply anesthetized with a lethal dose of pentobarbital. 
Immediately after sampling, blood was centrifuged to recover plasma which was stored at -80°C and 
extracted to quantify DXP and DXM as described after. For each time point, 5 mice out of 7 
underwent organ sampling after a cardiac puncture. Liver, spleen, kidneys, and lungs were removed 
and stored at -80°C for further dosing. PK analysis was performed using the PK solver plugin from 
Excel. 
2.12.1 DXP and DXM quantification in plasma 
To quantify DXP and DXM in plasma, an extraction process was developed. 100L of plasma samples 
were introduced into centrifugation tubes and 100L of the internal standards (IS) mixture, 
testosterone decanoate (TestD) for DXP and dexamethasone acetate (DXA) for DXM, both at 4g/mL 
in acetonitrile were added and vortexed for 30 seconds. 3mL of a 9/1 chloroform/methanol (v/v) 
mixture was added and tubes were vortexed vigorously for 3 minutes to precipitate proteins. 
Centrifugation was performed at 3500rpm (=1690g) for 30min (ST16R centrifuge, rotor TX-400, 
Thermo Scientific, France). The supernatant organic phase was recovered and evaporated using an 
evaporator under nitrogen gas flow (Sample concentrator, Stuart, UK). Dried samples were dissolved 
into 200L acetonitrile and DXP or DXM were quantified by HPLC-UV. Each sample was analyzed 
twice, once with the DXP quantification method, second with the DXM quantification method. 
A Waters 717 Plus autosampler chromatographic system was employed equipped with a Waters 
1525 binary HPLC pump, a Waters 2487 dual λ absorbance UV detector, and a Breeze software. The 
analysis was performed at 240nm wavelength using a SymmetryShieldTM RP18 column (5 µm, 
250×4.6 mm; Waters, Saint-Quentin-en-Yvelines, France). The column temperature was maintained 
at 40°C. The mobile phase was composed by a mixture of acetonitrile and milliQ water: 85/15 v/v for 
DXP and 35/65 v/v for DXM. The mobile phase flow rate was 1.2mL/min, the injection volume was 
50L and the run time was 30min. Retention times were 24min and 9min for DXP and DXM, 
respectively, 21min for TestD (IS of DXP) and 26min for DXA (IS of DXM). Calibration curves of DXP 
and DXM were linear, respectively in the range 0.5-100g/mL (R²=0.9997, y=0.2199x-0.0165, 
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LOQ=0.5µg/mL, LOQ=0.16µg/mL) and 0.1-100g/mL (R²=0.9974, y=1.056x+0.1445, LOQ=0.1µg/mL, 
LOQ=0.033µg/mL).  
Regarding short time points (10min, 20min), DXP and DXM concentrations were above the linearity 
range of the calibration curve.  A second calibration curve for each molecule was determined with 
50L plasma completed to 100L with milliQ water. Following extraction steps were the same as 
previously described. Calibration curves “50L plasma” of DXP and DXM were linear, respectively in 
the range 50-800g/mL (R²=0.9808, y=0.2229x-3.2128) and 20-400g/mL (R²=0.9986, y=0.7178x-
0.059). 
2.12.2 DXP and DXM quantification in organs 
Organs were homogenized in PBS using a micro-pestle coupled with a turbine at 2038rpm during the 
time needed to obtain a liquid preparation, approximately 5min. DXM and DXP were extracted from 
the homogenate using the same method than plasma extraction, beginning with 100µg of 
homogenate for liver and kidneys, 25µg for spleen and lungs completed up to 100µg with milliQ 
water. 100µL of internal standard mixture TestD and DXA at 4µg/mL was added and vortexed 30sec, 
followed by the addition of 3mL of 9/1 chloroform/methanol (v/v), vortexed for 3min and 
centrifuged in the same conditions as above. The organic phase was evaporated and 200µL 
acetonitrile was added and mixed during 1.5min. This final sample was analyzed by HPLC-UV, using 
the same conditions as plasma samples. 
3 RESULTS & DISCUSSION 
3.1 Formulation process  
Two different formulation processes were tested to produce DXP nanoparticles coated with 
phospholipids coupled to PEG. As DXP is highly hydrophobic and known to be prone to crystallization 
in aqueous suspension30, DSPE-PEG2000 was added to the prodrug to limit its crystallization and to 
inhibit Ostwald ripening. Indeed, Ostwald ripening due to the high DXP proportion was already 
described for DXP microemulsions31 and for palmitate derivatives such as ascorbyl palmitate 
nanocrystals. 32 DSPE-PEG2000 is an excipient mainly used in the formulation of clinically applied 
liposomes and in solid-lipid nanoparticles.33 To choose the process best suited for further IV 
administration of GCs nanoparticles, several DXP/DSPE-PEG2000 ratios were selected with a fixed DXP 
initial concentration of 5mg/mL. Both processes led to the formation of nanoparticles. When 
applying nanoprecipitation, the hydrodynamic diameter did not vary, regardless of the DXP/DSPE-
PEG2000 ratio with nanoparticles around 230-250nm (Figure 1a). For emulsion-evaporation, smaller 
nanoparticles whose diameter was in the range of 120-130nm were obtained, independently of the 
DXP/DSPE-PEG2000 ratio (Figure 1a). This difference can be explained when examining more closely 
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the process parameters. During nanoprecipitation, DXP was dissolved in acetone and DSPE-PEG2000 
was solubilized in water at 60°C. Heating the aqueous phase at 60°C eases the dissolution of the 
PEGylated lipid and promotes the diffusion of acetone in water during the injection step to favor the 
fast formation of nanoparticles. On the contrary, heating the aqueous phase during emulsion-
evaporation could lead to the fast evaporation of chloroform during the emulsion step with 
ultrasonication, resulting in the destabilization of the primary emulsion and no DXP-NPs formation. 
For this reason, we opted to dissolve at room temperature DSPE-PEG2000 with DXP in chloroform for 
the emulsion-evaporation process. Thereby, the presence of DXP and DSPE-PEG2000 together in 
chloroform favors their interaction and leads to the formation of smaller nanoparticles. The smaller 
size of emulsion-evaporation DXP-NPs may also arise from a reduced interfacial tension of the 
chloroform-water interface due to the presence of the PEGylated lipid. 
To determine the impact of DXP concentration on nanoparticle size, four DXP concentrations were 
then tested 1.25, 2.5, 5 and 10mg/mL for both formulation processes with a constant 2/1 DXP/DSPE-
PEG2000 ratio. Figure 1b clearly shows that dH increases as DXP concentration increases using the 
nanoprecipitation process. Very polydisperse nanoparticles of 300nm at a DXP concentration of 
10mg/mL were obtained. In the case of nanoprecipitation, nanoparticle size can be adjusted by 
tuning the DXP initial concentration. On the contrary, the emulsion-evaporation process led to the 
formation of monodisperse nanoparticles around 130nm, with a slight increase of size up to 170nm, 
for the highest concentration tested.  
Our rationale was to design a nanoparticle suspension with high drug concentration and low 
concentration of excipients for IV administration, the DXP/DSPE-PEG2000 5/2.5mg/mL conditions were 
therefore selected for remaining experiments. For both preparation methods, formulations were 
characterized and compared in terms of stability, entrapment efficiency, drug loading, and DSPE-PEG 
coating.  
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Figure 1. a. Impact of the DXP/DSPE-PEG2000 weight ratio on the size of the obtained nanoparticles 
(constant final DXP concentration of  5mg/mL). The ratios 3/1, 2/1, 1/1 and 2/3 were tested through 
nanoprecipitation (red circles) and emulsion-evaporation (blue squares) processes. b. Evaluation of 
the impact of DXP concentration in both nanoprecipitation (red circles) and emulsion-evaporation 
(blue squares) processes with a constant 2/1 DXP/DSPE-PEG2000 ratio. 
 
3.2 Size, zeta potential and stability over time 
After preparation of DXP/DSPE-PEG 5/2.5mg/mL nanoparticles by either nanoprecipitation or 
emulsion-evaporation, their size, polydispersity index (PdI) and zeta potential were followed during 
37 days to confirm the stability of the suspension (Figure 2). Formulation storage at 4°C and room 
temperature were compared. Emulsion-evaporation-prepared DXP-NPs stored at 4°C were clearly 
more stable in terms of size, PdI and zeta potential. Under 4°C storage, nanoparticle hydrodynamic 
diameter (dH) was kept around 130±3nm (Figure 2a) up to 37 days after preparation. Under the same 
storage conditions, the zeta potential and the PdI were stable around -50 to -60 mV and 0.2, 
respectively. On the contrary, at room temperature, size increased after 4 days and on day 14, a clear 
destabilization of the nanosuspension appeared, characterized by a size increase of 40%, associated 
with a rise of polydispersity and zeta potential (Figure 2a). On day 21 and later, no size and zeta 
potential measurements could be performed for samples stored at room temperature due to 
precipitation resulting from the formation of DXP crystals within the precipitate as evidenced by 
optical microscopy (Figure S1). By contrast, the nanoprecipitation process yielded stable 
nanoparticles which mean diameter remained around 230nm at 4°C and presented size increase at 
room temperature on day 37 due to their destabilization (figure 2b). DXP-NPs polydispersity index 
was kept below 0.2 highlighting a rather monodisperse population. The zeta potential was also stable 
ranging from -50 to -60mV. This high negative surface charge was able to promote electrostatic 
repulsion between nanoparticles and prevents aggregation and destabilization of the preparation. 
These nanoparticles prepared by either emulsion-evaporation or nanoprecipitation techniques, with 
high concentrations of DXP/DSPE-PEG2000 5/2.5mg/mL, present a clear advantage being long term 
stable at 4°C without the need of purification steps or freeze-drying. This characteristic is an 
important point in terms of ease of production.  
3.3 Morphology and internal structure of the nanoparticles 
TEM observations were consistent with dynamic light scattering measurements (Figure 3). Indeed, 
emulsion-evaporation process led to small spherical nanoparticles, with higher polydispersity than 
those obtained by nanoprecipitation. The mean diameter of the emulsion-evaporation-prepared 
nanoparticles was lower than 200nm. Figure 3b presents monodisperse and spherical DXP-NPs 
prepared by nanoprecipitation. Their hydrodynamic diameter above 200nm confirmed DLS studies. 
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No crystals or crystalline structure could be observed on these images. DXP-NPs suspensions were 
analyzed by X-ray diffraction to determine their internal structure. Using both formulation processes, 
the resulting DXP-NPs were analyzed the day of preparation and 3 weeks after storage at 4°C. They 
were compared to crystalline DXP form obtained from recrystallization in acetone that gives needle-
shaped crystals19,30. The diffractogram of recrystallized DXP after acetone evaporation is typical of a 
crystalline structure with many diffraction peaks (Figure 4 bottom) as described by Doi et al .30. By 
contrast, almost no diffraction peaks can be observed for DXP-NPs either freshly prepared or 3 weeks 
old, regardless of the preparation technique (Figure 4 top). The diffractogram of DXP-NPs presents a 
"bump" which is typical of the presence of an unorganized amorphous system. Results clearly show 
that neither DXP nor DSPE-PEG2000 present a crystalline organization. In addition, the amorphous 
nanoparticles appear stable upon storage at 4°C, a clear advantage for further clinical use. Therefore 
whatever the process of formulation, DXP-NPs remain amorphous and stable under storage at 4°C as 
no crystal is observed microscopically or detected by X-ray diffraction.  As demonstrated for other 
excipients such as Pluronic F12734 and HPMC35, the presence of DSPE-PEG2000 seems to slow down 
the nucleation and crystal growth of DXP in the suspension. During the formation of DXP-NPs, the 
DXP palmitate chain interacts with the stearate chains of DSPE-PEG2000 thanks to strong hydrophobic 
interactions introducing some disorder. This strong interaction might also be responsible for the 
limitation of Ostwald ripening. Moreover, the hydrophilic PEG chains exposed at nanoparticle surface 
improve stability by steric hindrance. 
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Figure 2. Size, PdI and zeta potential stability of DXP/DSPE-PEG2000 5/2.5 mg/mL nanoparticles, at 
room temperature (RT) or 4°C. a. emulsion-evaporation, b. nanoprecipitation. Results are presented 
as mean±SEM (n=5 at least). 
 
 
 
 
 15 
 
 
Figure 3. DXP/DSPE-PEG2000 5/2.5mg/mL nanoparticles imaged by TEM after negative staining. a. 
emulsion-evaporation and b. nanoprecipitation process. 
 
 
 
Figure 4. X-ray diffractogram of DXP-NPs obtained directly after their formulation (day 0, emulsion-
evaporation (red) and nanoprecipitation (purple)), or after 3 weeks storage at 4°C (emulsion-
evaporation (blue) and nanoprecipitation (orange)), and DXP crystals (green). 
 
3.4 Entrapment efficiency and drug loading 
During nanoparticles preparation, DSPE-PEG2000 is expected to associate strongly with DXP thanks to 
hydrophobic interactions between the distearoyl chains of DSPE-PEG2000 and the palmitate chain of 
DXP. Entrapment efficiency was determined by quantifying, on one hand, the amount of DSPE-
PEG2000 associated to DXP-NPs, and on the other hand, the amount of DXP in DXP-NPs as it is related 
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to the potential amount of DXM that could be delivered. A simple method of HPLC-ELSD that can 
separate and detect both components in a single injection on the same chromatogram was 
developed. After separation by ultracentrifugation, non-encapsulated DXP and DSPE-PEG2000 in the 
supernatant were quantified and their amount in NPs was calculated indirectly. The proportion of 
encapsulated DSPE-PEG2000 presented variations according to the formulation process (Figure 5a). 
Nanoprecipitation led to 20% of encapsulated DSPE-PEG2000 whereas 53% was encapsulated thanks 
to emulsion-evaporation process (p < 0.05, unpaired t-test). The difference of DSPE-PEG2000 
entrapment efficiency between the two processes, nanoprecipitation 20%w/w and emulsion-
evaporation 53%w/w, could be linked to DSPE-PEG2000 solvent affinity (acetone or chloroform) and its 
impact on hydrophobic interaction between lipids and DXP occurring during nanoparticles 
preparation. Considering the amounts of encapsulated DXP and DSPE-PEG2000, the DXP prodrug 
loading and the corresponding active drug DXM loading can be calculated (Figure 5b). 
Nanoprecipitated nanoparticles present a high DXP loading (91%w/w), corresponding to an 
equivalent of 56% of DXM of the DXP-NPs total mass. Emulsion-evaporation leads to 78%w/w DXP 
loading corresponding to an equivalent of 48%w/w DXM loading, meaning that half of the total mass 
of DXP-NPs is composed of the active drug. When comparing to literature, these drug loadings are 
very high. Indeed, the formulation of DXP in the lipid emulsion Limethason® exhibits a low drug 
loading of 4%w/w DXP/lipids resulting in an equivalent DXM loading of 2.5% w/w. We suspect that 
this low drug loading was chosen due to the possible issues of crystallization and stability of this 
formulation at higher DXP concentrations. Here, despite the differences of DSPE-PEG2000 
encapsulated by both methods, 98% of the initial amount of DXP was detected in DXP-NPs with no 
significant differences (p > 0.05, unpaired t-test). Irrespective of the formulation process and thanks 
to the presence of palmitate chain on dexamethasone, the highest possible drug entrapment 
efficiency was reached. 
 
Figure 5. a. DXP (red) and DSPE-PEG (blue) entrapment efficiency in DXP-NPs prepared by 
nanoprecipitation or emulsion-evaporation. b. Corresponding DXP (red) and equivalent DXM (light 
red) loading for both formulation processes. Results are presented as mean±SEM (n=7). 
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Because nanoparticle formulation process clearly impacts on the PEGylated lipid number in 
nanoparticles, we have calculated the area occupied by each PEG chain on nanoparticle surface in 
order to evaluate PEG density. To calculate this density, we need to hypothesize that 100% of PEG 
chains are situated on the surface of the nanoparticles and not in the matrix/core. Since PEG is 
hydrophilic and DSPE hydrophobic, it seems realistic that most of it stand at the surface of 
nanoparticles, with the DSPE moiety inserted in the matrix while the PEG chain is exposed in contact 
with water. 
For emulsion-evaporation, data used for PEG density calculation are =1.09g/cm3, the average 
diameter of the nanoparticles is d=130nm and the percentages of encapsulated DXP=98% and 
encapsulated DSPE-PEG2000=53% for a DXP/DSPE-PEG2000 5/2.5 mg/mL suspension. Using these data, 
the surface available per PEG chain on the surface of the nanoparticles formed by emulsion-
evaporation is therefore 0.93nm2/PEG. For nanoprecipitation process, after injecting correct values: 
=1.11g/cm3, d=230nm, one finds that the available surface per PEG chain is 1.18nm²/PEG. The 
emulsion-evaporation process was therefore considered as gold standard formulation method with 
small and stable nanoparticles, high drug loading and high PEG density, favorable to good opsonin 
repulsion. Indeed, to allow passive diffusion through high permeable vessels, nanoparticle size range 
of 50-400nm is preferred with better accumulation when size is below 200nm.36–39 Regardless of the 
formulation technique, DXP-NPs presented suitable characteristics for this type of indication. 
However, nanoparticles obtained by the emulsion-evaporation process, using a DXP concentration of 
5mg/mL, led to smaller and monodisperse nanoparticles that could be used in the treatment of 
inflammation diseases. Moreover, for IV administration, a nanoparticle suspension with a high 
concentration of active substance will be preferably chosen in order to inject a volume as small as 
possible. NP characterization suggests that DXP-NPs prepared by emulsion-evaporation method are 
optimally producing small and stable nanoparticles with high drug loading and high PEG density. 
3.4.1 Cytotoxicity and anti-inflammatory activity 
A range of DXP-NPs concentrations from 37.5µg/mL up to 450µg/mL (corresponding to 23.3-
280µg/mL eq.DXM) was tested and compared to the water-soluble free drug, dexamethasone 
sodium phosphate (DSP) on macrophages. According to ISO guideline for MTT assay, potential 
cytotoxicity is defined when cell viability decreases below 70% of the control.40 Figure 6 clearly shows 
DXP-NPs presented no cytotoxicity up to DXM equivalent concentration of 280µg/mL, whereas no 
decrease in cell viability was observed for DSP in the concentration range tested. In addition, 
280µg/mL (eq.DXM) is a rather high concentration that is unlikely to be reached during in vivo 
studies after IV injection. 
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Figure 6. Raw 264.7 macrophages viability after 24h exposure to DXP-NPs prepared by emulsion-
evaporation (green circles) or DSP solution (blue squares) at different concentrations. Concentrations 
are expressed as equivalent DXM. Results are presented as mean±SEM (n=3). 
 
To ensure that the anti-inflammatory activity of DXM was preserved after formulation, the release of 
pro-inflammatory cytokines (MCP-1, IL-10, IL-6, TNFα) by LPS-activated Raw 264.7 macrophages into 
the cell culture medium was quantified after their exposure to DXP-NPs at different concentrations 
(1; 10; 100µg/mL DXP) or free DSP at 82µg/mL, corresponding to 100µg/mL of DXP. A decrease of 
cytokines concentration was clearly observed resulting from the anti-inflammatory effect of DXP-NPs 
(Figure 7). The MCP-1 chemokine (Figure 7a) was strongly and significantly reduced by DXP-NPs in 
the presence of LPS. Regardless of DXP concentration in nanoparticles, no dose-effect was observed, 
meaning that the lower concentration of DXP-NPs (1µg/mL) was sufficient to yield the expected anti-
inflammatory effect. The same conclusions hold for the secretion of IL-10 (Figure 7b). Indeed, a 
significant reduction of IL-10 level was observed after treatment with DXP nanoparticles, regardless 
of DXP concentrations. Concerning IL-6 release (Figure 7c), results were more balanced. No 
significant reduction was detected for DXP nanoparticles and free dexamethasone, but a downward 
trend can be observed when comparing positive control and DXP-NPs activity. This result can be 
related to the usual classification of IL-6 as a simultaneous pro- and anti-inflammatory cytokine. 
Interestingly, DXP concentration in nanoparticles has an impact on TNFα release (Figure 7d). Indeed, 
only 100µg/mL DXP in nanoparticles could reduce significantly the release of this important pro-
inflammatory cytokine, whereas no effect was detected with free dexamethasone phosphate at the 
equivalent concentration.  
A control study was performed to ensure that DXP-NPs do not induce inflammation by themselves 
(Figure S2). All these results confirmed that the use of a prodrug and its formulation into 
nanoparticles does not affect the therapeutic activity of the drug. DXM is most probably released 
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from DXP-NPs due to the presence of esterases in the cell culture medium, as it was observed in 
plasma 41 or even in macrophage lysosomal compartments. Based on these promising results, in vivo 
studies were performed. 
 
 
Figure 7. Cytokine production by Raw 264.7 macrophages without LPS induction (C-) or with LPS 
induction 0.1µg/mL (C+), DXP nanoparticles at 1µg/mL DXP (LPS+DXP1), 10µg/mL (LPS+DXP10), 
100µg/mL (LPS+DXP100) or DSP solution at 82µg/mL corresponding to 100µg/mL of DXP 
(LPS+DSP82). Four cytokines were evaluated a) MCP-1, b) IL-10, c) IL-6 and d) TNF-α. Results are 
presented as mean±SEM (n=3) for all groups. Statistical analysis was performed with two-way 
ANOVA followed by Tukey’s post test using GraphPad Prism. * p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 indicates differences with positive control (C+). 
 
3.5 Pharmacokinetics and biodistribution 
To obtain a better understanding of the behavior of DXP-NPs after IV injection, their 
pharmacokinetics and biodistribution were determined. Dexamethasone palmitate is a prodrug and 
 20 
 
dexamethasone base (DXM) is the active drug released from DXP after ester bond hydrolysis. 
Thereby, DXM and DXP were quantified from mice plasma after DXP-NPs were intravenously 
injected. DXP-NPs were compared to control DSP, water-soluble prodrug of DXM (Figure 8a). Ten 
minutes after injection, DXM from DSP control solution was obviously eliminated very fast, reaching 
a plateau around 10% of the injected dose up to 48h. DXP plasmatic concentration decreases slowly 
until 8h after injection. After 8h, no DXP was detected in mice plasma. The prodrug is transformed 
into DXM, which plasmatic concentration presents a slow decrease for 18h. The main 
pharmacokinetic parameters were calculated according to a non-compartmental model (Figure 8b). 
The area under the curve (AUC0-∞) of DXM from nanoparticles 126400µmol*min/L, whereas DXM 
from control was 93600µmol*min/L meaning the active DXM molecule exposure in the body is 1.35 
times higher compared to injection of free dexamethasone. When comparing data up to 4h, the 
AUC(0-240) is 3.3 fold higher for DXM from nanoparticles. At Tmax, 10min for both, Cmax of DXM from 
nanoparticles, 327µmol/L (or 128.5µg/mL) is 5.8 times higher than the control, Cmax= 56µmol/L (or 
22.1µg/mL). Volumes of distribution (Vd) reveal DXP-NPs were less distributed in the organs and stay 
longer in the blood, with Vd for DXM from nanoparticles 1.8-fold lower than the control. However, 
elimination half-life and mean residence time (MRT) are higher for the control DSP, probably due to 
the plasmatic plateau observed. These data support the fact that DXP-NPs lead to a higher exposure 
after IV injection compared to the free drug, due to the enhanced pharmacokinetics properties of 
DXP-NPs. Nevertheless, DXP act as a prodrug, encapsulated into NPs and seems to be rapidly 
hydrolyzed to release free DXM in the blood.  
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Figure 8. a. Pharmacokinetics of DXP and DXM expressed as molar plasmatic concentration. Plasma 
concentrations of  DXP (green) and DXM (red) released from DXP nanoparticles and DXM (blue) 
released from DSP solution after IV injection of 12mg/kg (eq.DXM) on males DBA/1 healthy mice. 
Results are presented as mean±SEM (n=7). PK curves were significantly different up to 480min (6 
hours) (* p < 0.05, unpaired t-test). b. Corresponding pharmacokinetic parameters. 
 
Figure 9 presents the biodistribution of DXP-NPs and DSP control, both injected intravenously at 
12mg/kg (eq.DXM), in liver, spleen, kidneys, and lungs. Among the four organs, the liver presents the 
highest accumulation of DXM from nanoparticles with an increase up to 18% of the injected dose 40 
min after injection followed by a slow decrease until 48h. However, DXP and DXM liver 
concentrations from nanoparticles were clearly lower than the control DSP for the first-time points 
after injection. Less than 2% of the injected dose of drug or prodrug was detected in the kidneys. This 
presence is linked to the elimination of the molecules through urinary excretion. Very small 
quantities, lower than 1%, were detected in the lungs. After statistical analysis, a significant 
difference was found between DXM from DSP and DXM from DXP-NPs on the whole data in the 
spleen, whereas values in the liver, kidneys, and lungs were not significantly different (unpaired t-
test). Pharmacokinetics results are correlated with biodistribution evaluation. In the liver, the small 
amounts of DXP detected indicate that PEGylation of nanoparticles allows a reduction of their 
opsonization, helping them to escape from the immune system recognition in the bloodstream. The 
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presence of DXM from DXP-NPs and from DSP in the liver is linked to the intrinsic hepatic 
accumulation of DXM.42 On the other hand, DXP spleen concentrations from the nanoparticles were 
significantly higher compared to DSP. Even though DXP in spleen represents less than 2% of the 
injected dose, its highest concentration in this organ could be explained by the presence of the PEG 
at the surface of the nanoparticles. 43 Indeed, the spleen is less accessible than liver due to its low 
vascularization, however, the modified pharmacokinetics properties of DXP-NPs induce more 
accumulation in this organ compared to free drug. Very low DXP quantities were observed in the 
lungs proving no crystallization or aggregation of the particles occurred after IV injection. DXP-NPs 
stability in the blood is therefore attested. 
 
 
 
Figure 9. Biodistribution of DXP-NPs (DXP in green, DXM in red) and DSP solution (DXM in blue) after 
12mg/kg (eq.DXM) injected dose on male DBA/1 mice. Quantification was performed in a) liver (not 
significant (n.s.) between DXM from DSP and DXM from NPs, unpaired t-test), b) kidney (n.s. 
between DXM from DSP and DXM from NPs, unpaired t-test), c) spleen (p< 0.05 between DXM from 
DSP and DXM from NPs, unpaired t-test) and d) lungs (n.s. between DXM from DSP and DXM from 
NPs, unpaired t-test). Results are presented as mean±SEM (n=5). 
 
4 CONCLUSIONS 
We have succeeded to formulate a hydrophobic prodrug of dexamethasone into PEGylated solid lipid 
nanoparticles using two different formulation processes. Either nanoprecipitation or emulsion-
evaporation leads to the formation of stable nanoparticles. Nanoparticle size can be tuned between 
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130 and 300nm depending on the process, the prodrug/lipid ratio, and the prodrug concentration. A 
very high prodrug entrapment efficiency of 98% w/w was reached for both processes, corresponding 
to a very high equivalent DXM loading around 50% w/w. In terms of PEGylated lipid association, 
emulsion-evaporation method enables 53% of DSPE-PEG2000 entrapment whereas only 20% was 
obtained by nanoprecipitation. Since DXP-NPs obtained by emulsion-evaporation were smaller in size 
and allowed to obtain very dense PEG brushes on their surface with an available surface of 
0.93nm2/PEG chain, they were considered the perfect candidates for further in vitro and in vivo 
evaluation. After IV injection of DXP-NPs, the release of DXM in plasma was clearly controlled up to 
18h compared to the free drug rapidly eliminated from plasma after administration. These prodrug 
nanoparticles represent a promising treatment for chronic inflammatory diseases as they possess all 
the prerequisites to accumulate in inflamed tissues after extravasation. 
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